ES2094342T3 - Nuevos complejos con contenido en acido nucleico, absorbibles, a traves de endocitosis, en celulas eucarioticas superiores. - Google Patents

Nuevos complejos con contenido en acido nucleico, absorbibles, a traves de endocitosis, en celulas eucarioticas superiores.

Info

Publication number
ES2094342T3
ES2094342T3 ES92903641T ES92903641T ES2094342T3 ES 2094342 T3 ES2094342 T3 ES 2094342T3 ES 92903641 T ES92903641 T ES 92903641T ES 92903641 T ES92903641 T ES 92903641T ES 2094342 T3 ES2094342 T3 ES 2094342T3
Authority
ES
Spain
Prior art keywords
nucleic acid
complexes
endocytosis
eucarytic
absorbable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92903641T
Other languages
English (en)
Inventor
Max L Birnstiel
Matthew Cotten
Ernst Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Genentech Inc
Original Assignee
Boehringer Ingelheim International GmbH
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Genentech Inc filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2094342T3 publication Critical patent/ES2094342T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Abstract

COMPLEJOS ENTRE CONJUGADOS DE FACTORES DE UNION E INTERNALISACION Y ACIDO NUCLEINICO QUE PUEDEN ABSORBERSE EN GRAN NUMERO DE CELULAS EUCARIOTICAS POR ENDOCITOSIS CONTIENEN EN FORMA UNIDA NO COVALENTE UNA O VARIAS SUSTANCIAS AFINES DE ACIDO NUCLEINICO QUE PUEDEN ELEVAR LA EFICIENCIA DE LA ABSORCION DEL COMPLEJO EN LA CELULA. LA SUBSTANCIA AFIN DEL ACIDO NUCLEINO UNIDA NO COVALENTEMENTE ES IDENTICA AL FACTOR DE UNION O SUSTANCIA DE INTERNALISIACION ES PREFERENTES TRANSFERRICA. PROCEDIMIENTO PARA OBTENER EL COMPLEJO, Y UN PROCEDIMIENTO PARA INTRODUCIR ACIDO NUCLEICO EN GRAN NUMERO DE CELULAS EUCARIOTICAS. PREPARADO FARMACEUTICO QUE CONTIENE COMPLEJO CON UN ACIDO NUCLEINICO TERAPEUTICO.
ES92903641T 1991-02-12 1992-02-01 Nuevos complejos con contenido en acido nucleico, absorbibles, a traves de endocitosis, en celulas eucarioticas superiores. Expired - Lifetime ES2094342T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4104186A DE4104186A1 (de) 1991-02-12 1991-02-12 Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe

Publications (1)

Publication Number Publication Date
ES2094342T3 true ES2094342T3 (es) 1997-01-16

Family

ID=6424859

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92903641T Expired - Lifetime ES2094342T3 (es) 1991-02-12 1992-02-01 Nuevos complejos con contenido en acido nucleico, absorbibles, a traves de endocitosis, en celulas eucarioticas superiores.

Country Status (6)

Country Link
EP (1) EP0571414B1 (es)
JP (1) JPH06504993A (es)
AT (1) ATE142890T1 (es)
DE (2) DE4104186A1 (es)
ES (1) ES2094342T3 (es)
WO (1) WO1992013570A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
WO1993010819A1 (en) * 1991-11-26 1993-06-10 Alkermes, Inc. Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
FR2719316B1 (fr) * 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
JPH0889278A (ja) * 1994-09-29 1996-04-09 Ajinomoto Co Inc 遺伝子導入用修飾蛋白質及びその製法
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
EP0874910A4 (en) * 1995-06-07 1999-04-21 Life Technologies Inc ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
FR2736642B1 (fr) * 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
FR2755976B1 (fr) * 1996-11-15 1999-01-15 Idm Immuno Designed Molecules Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
DE69838584T2 (de) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
US6927278B1 (en) * 1998-09-01 2005-08-09 Trustees Of The University Of Pennsylvania Peptide scaffolds for transfer of molecules into eukaryotic cells
EP2298728A1 (en) 1998-11-12 2011-03-23 Life Technologies Corporation Transfection reagents
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6902933B2 (en) * 2000-11-03 2005-06-07 Regents Of The University Of Michigan Surface transfection and expression procedure
WO2004096117A2 (en) * 2003-05-02 2004-11-11 Xpression Antibody Therapeutics, Inc. Drug delivery systems comprising transferrin-nucleic acid conjugates
ATE469984T1 (de) 2003-12-01 2010-06-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
EP2099496A2 (en) * 2006-12-08 2009-09-16 Massachusetts Institute of Technology Delivery of nanoparticles and/or agents to cells
MY173826A (en) 2012-11-15 2020-02-24 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
AU2015260725B2 (en) 2014-05-14 2021-02-25 Targimmune Therapeutics Ag Improved polyethyleneimine polyethyleneglycol vectors
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0387775T3 (da) * 1989-03-16 1996-11-04 Boehringer Ingelheim Int Genetisk enhed til inhibering af funktionen af RNA
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
DE59106279D1 (de) * 1990-05-18 1995-09-21 Genentech Inc Neue protein-polykation-konjugate.

Also Published As

Publication number Publication date
DE59207189D1 (de) 1996-10-24
ATE142890T1 (de) 1996-10-15
WO1992013570A2 (de) 1992-08-20
EP0571414A1 (de) 1993-12-01
EP0571414B1 (de) 1996-09-18
WO1992013570A3 (de) 1992-10-29
JPH06504993A (ja) 1994-06-09
DE4104186A1 (de) 1992-08-13

Similar Documents

Publication Publication Date Title
ES2094342T3 (es) Nuevos complejos con contenido en acido nucleico, absorbibles, a traves de endocitosis, en celulas eucarioticas superiores.
NO941155L (no) Nye konjugater for innföring av nukleinsyre i höyere eukariotiske celler
AU7366687A (en) Coupling agents for radiolabeling proteins
ES2112982T3 (es) Composicion relativa a una bebida dietetica.
AU1375188A (en) Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy
EA199700266A1 (ru) Фармацевтическая композиция, содержащая выбранные гидраты карбоната лантана
TR199901690T2 (xx) Yeni solunum form�lasyonu, form�lasyonu haz�rlamaya y�nelik i�lem.
EP0294703A3 (en) Bifunctional antibody constructs and method for selectively destroying cell populations
BR9712265A (pt) "kit de estrutura transportável"
ES2010226A6 (es) Un procedimiento para producir una preparacion farmaceutica estable que contiene un factor estimulante de colonias de granulocitos
DK154537C (da) Hurtig-disintegrerende komprimerede laegemiddelpraeparater
BR7905566A (pt) Aperfeicoamento na preparacao de paineis de particulas e composicao estavel ao armazenamento
GR3036634T3 (en) Novel protein polycation conjugates.
GR80698B (en) N-cyclized benzenesulfonamides, process for the preparation thereof and their use as active substances in pharmaceutical compositons
AU586988B2 (en) Solid drug formulations and stable suspensions
ATE98130T1 (de) Kombination von angiotensin-converting-enzymehemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln.
ES2150421T3 (es) Nuevos conjugados, consistentes en una glicoproteina y una sustancia que se fija a acidos nucleicos.
JPS5554895A (en) Stable peroxidase-containing composition
Chugaj The relative abundance of nitrogen and oxygen in the type II supernovae.
EP0252033A3 (en) Utilization of the "gel" pharmaceutical form containing n-(2.6-dichloro-m-tolil)-anthranilic acid (mechlophenamic acid) utilizable in therapy for topical usage
GB8828320D0 (en) Improvements in/relating to transportation & storage arrangements
ATE46242T1 (de) Verdampfervorrichtung fuer in feste traegermaterialien eingelagerte wirkstoffe, wie pyrethrum.
ZA885705B (en) Antibody-enzyme conjugates in combination with products for the delivery of cytotoxic agents to tumor cells

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 571414

Country of ref document: ES